Status:
COMPLETED
A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice
Lead Sponsor:
Merck KGaA, Darmstadt, Germany
Collaborating Sponsors:
Merck Serono Limited, UK
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study is a multi-centre retrospective observational research study which will be conducted in UK centres with specialised liver surgical services. The study will involve retrospective review of ...
Eligibility Criteria
Inclusion
- Patients who had mCRC and metastases confined to the liver
- Patients in whom downsizing regimens are recommended
- Patients in whom downsizing treatment included cetuximab
- Patients referred to Hepatobiliary Multi Disciplinary Team (HPB MDT) between 01.01.2010-31.03.2011
Exclusion
- Patients who are considered to have immediately resectable liver metastases as determined by the HPB MDT
- Patients who are considered to have never resectable liver metastases as determined by the HPB MDT
- Patients who were aged less than 18 at date of initiation of cetuximab
- Patients who are enrolled in a clinical trial during the data collection period
- Patients who are receiving private healthcare for the treatment of mCRC
- According to Summary of Product Characteristics (SmPC)
Key Trial Info
Start Date :
November 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01460745
Start Date
November 1 2011
End Date
December 1 2012
Last Update
February 4 2014
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Merck Serono Research Site
Bristol, United Kingdom
2
Merck Serono Research Site
Liverpool, United Kingdom
3
Merck Serono Research Site
London, United Kingdom
4
Merck Serono Research Site
Manchester, United Kingdom